The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Cancer Treatment Centers of America launch fertility preservation program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CANCER TREATMENT CENTERS OF AMERICA launched a fertility preservation program, OncoPrez, at its hospitals in Chicago, Philadelphia and Tulsa.

The program makes discussions about fertility and family planning an integral part of treatment planning for all men and women of childbearing years. The program will be offered at CTCA hospitals in Atlanta and Phoenix in early 2015.

Each CTCA hospital in the program has identified a local, dedicated fertility center to provide preservation services. Patients who are interested in exploring fertility preservation are provided with a direct referral to a reproductive specialist who will work collaboratively with the patient’s CTCA oncology team.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account